Clinical Trial

Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 7, 2023 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-07-28; most recent amendment 2023-12-05.
Status change: Not Yet Recruiting → Recruiting 2023-01-30
Trial Details
NCT Number NCT04992780
Lead Sponsor University of Kansas Medical Center
Conditions Non Small Cell Lung Cancer Stage
Enrollment 50 participants
Start Date 2022-02-25
Primary Completion 2025-10 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2023-12-07